Comments of R. Glück

Abstract

This paper discusses several liposomal approaches: A T-independent response against hapten or lipopolysaccharide by the addition of a T-epitope (HA2 molecule of influenza); the same response against a synthetic peptide-based vaccine; finally the first commercial liposomal hepatitis A vaccine is discussed.